BRAF and neoplasm: Nowadays, testing for somatic tumor mutations in RAS and BRAF is mandatory to select the most appropriate treatment for CRC patients, and characterization of microsatellite instability (MSI) status of CRC tumor is assessed to evaluate the use of immune checkpoint inhibitors [12,13].